illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. Precision BioSciences
Company logo

Precision BioSciences | Sustainability Performance

https://precisionbiosciences.com
Linkedin

Develops genetic editing and biopharmaceutical solutions, focusing on oncology and other therapeutic areas.

2006

United States

51 - 200 employees

Biotechnology

$25M - 100M in revenue

Not profitable

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#5766
Overall
#1233
in United States
#113
in Biotechnology

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Arcturus Therapeutics

United States, Hospital & Health Care, Biotechnology


Company logo
NeueHealth

United States, Hospital & Health Care, Hospital & Health Care


Company logo
Envista

United States, Hospital & Health Care, Medical Device

Market cap

152.0M $, 2026▲26.3% YoY

Revenue

68.0M $, 2024▲29.4% YoY

R&D intensity

82.35% 2024

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

152.0M $, 2026▲26.3% YoY

Revenue

68.0M $, FY2024▲29.4% YoY

EBITDA

-24.0M $, FY2024▼9.1% YoY

Operating margin

-38% Industry: -370▼135.7% YoY

Revenue & EBITDA

$68.0MFY2024 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-58.7M 2024▼47.1% YoY

Capex

0.0 2024▼NaN% YoY

Debt/equity ratio

0.4 Industry: 2▼NaN% YoY

R&D intensity

82.3%FY2024

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

9.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.0

▲ 13.5%

2022

0.0

▼ 11.7%

2023

0.1

▼ 7.8%

2024

0.3

2031

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Available

45%
Independent Directors

5 out of 11 incl. management

Powered by illuminem

Overall score

42

Environment

50

Social

56

Governance

18

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Sustainability employees



    Available in
    Scale package

    Access
  • Email

  • Email